Enliven Therapeutics, Inc. (ELVN) Stock Price & Analysis

Enliven Therapeutics, Inc. (ELVN) closed at USD 44.78 on Wednesday, October 28, 2026, up 2.49% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 43.69; the Oct 28, 2026 session ranged USD 43.39–44.94 on volume of 1,261,396 shares. Market capitalization is $3.28B, with a 52-week range of USD 14.79–62.32 (NMS). Source: Nexqual, retrieved October 29, 2026 at 07:30 UTC.

Also available as compact Markdown for AI agents: nexqual.com/ELVN.md

Key facts (ELVN)

• Insider open-market sales, last ~7 months: 18 Form 4 filings, $65.8M; 3 not under a Rule 10b5-1 plan ($52.3M); 5 by opportunistic insiders (0 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.79 on a 1–5 scale) (14 analysts), mean target USD 74.42 (range 69–82).
• Total return with dividends: 1Y +97.7% vs S&P 500 +13.6%; 5Y +211.0% vs S&P 500 +79.8%.
• Next earnings: 2026-11-11, EPS estimate USD -0.45, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ELVN)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (ELVN)

P/B 3.7x · FCF yield -2.04% · Earnings yield -3.23%

Insider sales (SEC Form 4, open-market, last ~7 months) (ELVN)

15 of 18 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (ELVN)

Consensus Buy (mean 1.79 on a 1–5 scale), 14 analysts; mean target USD 74.42 (low 69, high 82).

Rating changes, last 120 days:

Total return (dividends reinvested) (ELVN)

ELVN earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

ELVN recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

ELVN analyst estimates and revisions

Key Statistics (as of October 29, 2026 at 07:30 UTC)

Technical Analysis (ELVN)

Nexqual's technical model rates ELVN "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 07:30 UTC.

Analyst Ratings (ELVN)

Wall Street analysts rate ELVN "Buy" based on 14 analysts, with a mean price target of USD 74.42 (range USD 69–82), per Nexqual as of October 29, 2026 at 07:30 UTC.

Earnings (ELVN)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 07:30 UTC.

Financials & Fundamentals (ELVN)

Source: Nexqual, October 29, 2026 at 07:30 UTC.

Financial Health Score (ELVN)

Nexqual rates Enliven Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 07:30 UTC.

Ownership (ELVN)

Source: Nexqual, October 29, 2026 at 07:30 UTC.

Leadership (ELVN)

Enliven Therapeutics, Inc. is led by Richard A. Fair, CEO, President & Director, per Nexqual as of October 29, 2026 at 07:30 UTC.

Major Backers & Investors (ELVN)

Notable institutional backers of Enliven Therapeutics, Inc. include FMR, LLC, Orbimed Advisors LLC., Polar Capital Holdings PLC, according to Nexqual as of October 29, 2026 at 07:30 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 07:30 UTC.

From Enliven Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)

Key Strengths & Strategy (as disclosed to the SEC)

• However, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and, if granted, the length of such extensions.
• Although we take steps to protect our proprietary information, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to or disclose our technology.
• Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection for our product candidates, technology and know-how, to operate without infringing the proprietary or intellectual property rights of others and to prevent others from infringing our proprietary or intellectual property rights.
• We may also rely on trade secrets, know-how, trademarks, continuing technological innovation and licensing opportunities to develop and maintain our proprietary and intellectual property position.

Legal & Regulatory Risks (Item 1A, quoted)

• The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.
• We received orphan drug designation for ELVN-001. We may not be able to obtain additional orphan drug designations or obtain or maintain orphan drug exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA, EMA or other comparable foreign regulatory authorities, from approving competing products.
• We may face difficulties from changes to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.
• We may also be subject to federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:30 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt